



PRESS RELEASE

## ***MolMed participates at the first annual meeting of the International Academy for Clinical Hematology ("IACH").***

***The therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours presented at the first edition of the summit that brings together the main international excellences of clinical hematology.***

Milan (Italy), September, 29<sup>th</sup> 2018 – MolMed S.p.A. (MLMD.MI) ("the Company"), clinical stage biotechnology company focusing on research, development, manufacturing, and clinical validation of cell & gene therapies to treat cancer and rare diseases, participates today in Paris at the first annual meeting of the International Academy for Clinical Hematology ("IACH") with a symposium entitled "*Engineering Immune Effector Cells: an European Perspective*", where the therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours will be presented in three different sessions.

The Meeting IACH, at its first edition, hosts the world's leading hematology experts with the aim to facilitate scientific interaction and formulate recommendations for the clinical practice of the field.

The symposium organized by MolMed within IACH, wants to provide an update on the latest developments at a European level in the field of cell therapy in the treatment of hematological diseases, illustrating the results obtained from its proprietary products.

The symposium includes three sessions: in the first one, Fabio Ciceri, Clinical Director of the Research Division of Regenerative Medicine, Cell and Gene Therapy and Director of the Hematology and Bone Marrow Transplantation Unit at San Raffaele Scientific Institute in Milan, will present the therapeutic potential of Zalmoxis®, the first patient specific cell therapy used in combination with the haploidentical transplantation of hematopoietic stem cells in the treatment of leukemia and other high risk hematologic tumours ("*Suicide-gene donor T-cells: Zalmoxis clinical benefit in haploidentical stem cell transplantation*").

*"Allogeneic transplantation from family haploidentical donors is an increasingly used transplant modality replacing the levelling-off use of unrelated donors. However, haploidentical transplantation is still limited by a significant rate of infectious-related mortality and leukemia relapse associated with an impaired post-transplant immune reconstitution"* Professor Ciceri commented *"Unmanipulated donor lymphocyte infusions is a potential solution to such limitation but still limited by consequent severe Graft-versus-Host reaction. Zalmoxis® (donor T lymphocytes modified to include TK suicide gene) is a cell therapy product with an adjunctive effect to haploidentical transplantation offering a fast and wide immune reconstitution with a contemporary control of GvHD"*.

During the second session Monica Casucci, Senior Post Doc Leukemia Immunotherapy Group, Division of



Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Hospital Scientific Institute, Milan, in the presentation titled "*Optimized CD44v6 CAR-T cell therapeutics for Acute Myeloid Leukemia and Multiple Myeloma*" will summarize the preclinical data on the efficacy and safety profile of CAR T CD44v6 in blood tumours.

Mohamad Mohty, Head of the Hematology Department at the Saint-Antoine Hospital and University of Pierre and Marie Curie in Paris, will close the symposium with a session on the advancement of CAR-T therapies in the treatment of myeloma ("*CAR-T cells for myeloma: where do we stand?*"). Professor Mohamad Mohty commented: "*This symposium demonstrates the development of CAR-T cells therapies as well as other cellular immunotherapies for treating haematological neoplasms. The field of cellular immunotherapy for cancer is an increasingly exciting and fast-moving area. But a particularly important question is whether CAR T-cell technology might be sustainable and able to target solid tumours in the next years. There are indications that researchers and companies might be able to develop these kind of products thanks also the biotech industry contribution to an important scientific meeting as IACH*".

A detailed program of the event is available at the link <http://iach2018.cme-congresses.com/program/>

### *About MolMed*

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a new CAR pipeline based on Chimeric Antigen Receptor; the most advanced product, the CAR-T CD44v6, currently in advanced preclinical development, and is potentially effective both for some hematological malignancies and several solid epithelial tumors. Following the authorization request submitted to European Regulatory Agencies, MolMed plans to commence during the first half of 2019, human clinical trials in the AML and MM indications. In addition, the Company is developing a new CAR pipeline, both autologous and allogeneic, the last one based on NK (Natural Killer) cells. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### *For further information:*

**Ilaria Candotti**  
*Investor Relations & Communication Manager*

**Marcella Ruggiero**  
*Press agent*



PRESS RELEASE

MolMed S.p.A.  
phone: +39 02 21277.205  
fax: +39 02 21277.325  
e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

SEC Relazioni Pubbliche e Istituzionali s.r.l.  
phone: +39 02 6249991  
mobile +39 335 214241  
e-mail: [ruggiero@secp.com](mailto:ruggiero@secp.com)